DK2532680T3 - Medicinsk sammensætning til behandling og/eller forebyggelse af cancer - Google Patents

Medicinsk sammensætning til behandling og/eller forebyggelse af cancer Download PDF

Info

Publication number
DK2532680T3
DK2532680T3 DK11739867.7T DK11739867T DK2532680T3 DK 2532680 T3 DK2532680 T3 DK 2532680T3 DK 11739867 T DK11739867 T DK 11739867T DK 2532680 T3 DK2532680 T3 DK 2532680T3
Authority
DK
Denmark
Prior art keywords
cancer
prevention
treatment
medical composition
medical
Prior art date
Application number
DK11739867.7T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of DK2532680T3 publication Critical patent/DK2532680T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23Immunoglobulins specific features characterized by taxonomic origin from birds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK11739867.7T 2010-02-04 2011-02-04 Medicinsk sammensætning til behandling og/eller forebyggelse af cancer DK2532680T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010023452 2010-02-04
PCT/JP2011/052384 WO2011096519A1 (ja) 2010-02-04 2011-02-04 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
DK2532680T3 true DK2532680T3 (da) 2015-07-20

Family

ID=44355513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11739867.7T DK2532680T3 (da) 2010-02-04 2011-02-04 Medicinsk sammensætning til behandling og/eller forebyggelse af cancer

Country Status (16)

Country Link
US (1) US8709418B2 (da)
EP (1) EP2532680B1 (da)
JP (1) JP5845899B2 (da)
KR (1) KR101758117B1 (da)
CN (1) CN102822199B (da)
AU (1) AU2011211684B2 (da)
BR (1) BR112012019098B8 (da)
CA (1) CA2788547C (da)
DK (1) DK2532680T3 (da)
ES (1) ES2543174T3 (da)
HU (1) HUE025678T2 (da)
MX (1) MX340017B (da)
PL (1) PL2532680T3 (da)
PT (1) PT2532680E (da)
RU (1) RU2567657C2 (da)
WO (1) WO2011096519A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
MX2012008991A (es) * 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2583777T3 (es) * 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
JP6003650B2 (ja) 2011-08-04 2016-10-05 東レ株式会社 膵臓癌の治療及び/又は予防用医薬組成物
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT3351630T (pt) 2011-08-04 2019-12-30 Toray Industries Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
EP2740798B1 (en) 2011-08-04 2016-12-07 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR101980557B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX360208B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2013223137B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CA2864869C (en) 2012-02-21 2021-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
RU2633505C2 (ru) 2012-02-21 2017-10-12 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
PL2832365T3 (pl) * 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
CN104471404B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
HUE043162T2 (hu) 2012-07-19 2019-08-28 Toray Industries Eljárás rák detektálására
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び/又は予防用医薬組成物
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
BR112019008335A2 (pt) * 2016-10-28 2020-01-28 Toray Industries conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
KR102120223B1 (ko) 2017-12-08 2020-06-08 세종대학교산학협력단 암의 예방 또는 치료용 의약 조성물
WO2019189780A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Her2を標的とする免疫結合体
AU2020291014A1 (en) 2019-06-13 2022-01-27 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US20220347310A1 (en) 2019-09-30 2022-11-03 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
BR112022018161A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
WO2021182573A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2021182572A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20220152309A (ko) 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4119157A4 (en) 2020-03-12 2024-03-27 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
EP4146282A1 (en) 2020-05-08 2023-03-15 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
KR20230051189A (ko) 2020-08-13 2023-04-17 볼트 바이오테라퓨틱스 인코퍼레이티드 피라졸로아제핀 면역접합체, 및 그의 용도
AU2022296193A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3225422A1 (en) 2021-06-23 2022-12-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023008461A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び/又は予防のための医薬品
CN117693363A (zh) 2021-07-27 2024-03-12 东丽株式会社 用于癌的治疗和/或预防的药品
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
JPWO2023033129A1 (da) 2021-09-03 2023-03-09
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2388822A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
PL366626A1 (en) 2000-03-29 2005-02-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DK1391511T3 (da) 2001-05-11 2008-09-29 Kirin Pharma Kk Humant kunstigt kromosom indeholdende human antistof lambda-let-kæde-gen
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
CA2504144A1 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
DK1730191T3 (da) 2004-03-30 2011-10-17 Glaxo Group Ltd Immunglobulin som binder HOSM
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
RU2297241C2 (ru) * 2004-11-22 2007-04-20 Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития Химерный белок для лечения злокачественных лимфом
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
JP5006802B2 (ja) 2005-02-18 2012-08-22 チルドレンズ メディカル センター コーポレイション 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのCyr61
AU2006223374B2 (en) 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP2010023452A (ja) 2008-07-24 2010-02-04 Seiko Epson Corp 印刷装置、及びデータ通信方法
KR20160127146A (ko) 2008-08-05 2016-11-02 도레이 카부시키가이샤 면역 유도제
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
JP6003650B2 (ja) 2011-08-04 2016-10-05 東レ株式会社 膵臓癌の治療及び/又は予防用医薬組成物
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
PT3351630T (pt) 2011-08-04 2019-12-30 Toray Industries Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro

Also Published As

Publication number Publication date
CN102822199A (zh) 2012-12-12
WO2011096519A1 (ja) 2011-08-11
CA2788547C (en) 2018-06-05
ES2543174T3 (es) 2015-08-17
AU2011211684B2 (en) 2014-09-25
EP2532680A1 (en) 2012-12-12
KR20120125327A (ko) 2012-11-14
BR112012019098B1 (pt) 2021-07-06
EP2532680A4 (en) 2013-11-27
BR112012019098A2 (pt) 2018-03-27
RU2567657C2 (ru) 2015-11-10
US8709418B2 (en) 2014-04-29
BR112012019098B8 (pt) 2021-08-17
RU2012137505A (ru) 2014-03-10
CN102822199B (zh) 2014-10-15
PT2532680E (pt) 2015-09-14
JP5845899B2 (ja) 2016-01-20
MX2012008996A (es) 2012-09-07
MX340017B (es) 2016-06-22
EP2532680B1 (en) 2015-04-29
AU2011211684A1 (en) 2012-08-23
EP2532680A9 (en) 2014-12-17
PL2532680T3 (pl) 2015-10-30
JPWO2011096519A1 (ja) 2013-06-13
CA2788547A1 (en) 2011-08-11
KR101758117B1 (ko) 2017-07-14
US20120321641A1 (en) 2012-12-20
HUE025678T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
DK2532680T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2532366T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK3351630T3 (da) Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
DK2322221T3 (da) Farmaceutisk sammensætning til behandling og forebyggelse af cancer
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3351558T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
EP2832365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF LIVER CANCER
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP2532743A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
IL225471B (en) Preparations for the prevention and treatment of cancer
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
DK2558133T3 (da) Coatinger til fremstillingen og anvendelse af polyhydroxyalkanoat-lægemiddelindretninger
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
DK2407151T3 (da) Sammensætning til behandling af hud- og/eller neglelæsioner
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
EP2651439A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION